Dabbagh Ohadi Mohammad Amin, Maroufi Seyed Farzad, Mohammadi Mohammad Reza, Hosseini Siyanaki Mohammad Reza, Khorasanizadeh MirHojjat, Kellner Christopher P
Departments of Pediatric Neurosurgery Children's Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Neurosurgical Research Network (NRN), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Department of Neurosurgery, Tehran University of Medical Sciences, Tehran, Iran.
World Neurosurg. 2024 Feb;182:52-57. doi: 10.1016/j.wneu.2023.11.049. Epub 2023 Nov 17.
Subarachnoid hemorrhage (SAH) is a cerebrovascular disorder with significant mortality and morbidity. Neural injury in SAH is mediated through a variety of pathophysiological processes. Currently available treatments are either nonspecific in targeting the basic pathophysiological mechanisms that result in neural damage in SAH, or merely focus on vasospasm. Ferroptosis is a type of programmed iron dependent cell death, which has received attention due to its possible role in neural injury in SAH. Herein, we review how intracellular iron overload mediates the production of reactive free radicals and lipid peroxidation through a variety of biochemical pathways in SAH. This in turn results in induction of ferroptosis, as well as exacerbation of vasospasm. We also discuss several therapeutic agents that have been shown to inhibit ferroptosis through targeting different steps of the process. Such agents have proven effective in ameliorating vasospasm, neural damage, and neurobehavioral outcomes in animal models of SAH. Human studies to test the safety and efficacy of intrathecal or parenteral administration of the inhibitors of ferroptosis in improving outcomes of SAH patients are warranted. There are currently a few ongoing clinical trials pursuing this therapeutic concept, the results of which will be critical to determine the value of ferroptosis as a novel therapeutic target in SAH.
蛛网膜下腔出血(SAH)是一种具有显著死亡率和发病率的脑血管疾病。SAH中的神经损伤是通过多种病理生理过程介导的。目前可用的治疗方法要么在针对导致SAH神经损伤的基本病理生理机制方面缺乏特异性,要么仅仅专注于血管痉挛。铁死亡是一种程序性铁依赖性细胞死亡,因其在SAH神经损伤中的可能作用而受到关注。在此,我们综述细胞内铁过载如何通过SAH中的多种生化途径介导活性自由基的产生和脂质过氧化。这反过来又导致铁死亡的诱导以及血管痉挛的加剧。我们还讨论了几种已被证明通过靶向该过程的不同步骤来抑制铁死亡的治疗药物。这类药物已被证明在改善SAH动物模型中的血管痉挛、神经损伤和神经行为结果方面有效。有必要进行人体研究以测试鞘内或胃肠外给予铁死亡抑制剂在改善SAH患者预后方面的安全性和有效性。目前有一些正在进行的临床试验遵循这一治疗理念,其结果对于确定铁死亡作为SAH新治疗靶点的价值至关重要。